Cargando…

Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report

Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Daoan, Tang, Shuxian, Li, Dong, Zhao, Weiqing, Wei, Wei, Fang, Cheng, Ji, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/ https://www.ncbi.nlm.nih.gov/pubmed/35946524 http://dx.doi.org/10.1097/CAD.0000000000001368

Ejemplares similares

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
por: Hu, Xingsheng, et al.
Publicado: (2023)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
por: Liu, Xiao-yun, et al.
Publicado: (2020)

A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects
por: Zhu, Songlin, et al.
Publicado: (2020)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
por: Chen, Ting, et al.
Publicado: (2023)

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
por: Xu, Ziyi, et al.
Publicado: (2023)

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
por: Cheng, Daoan, et al.
Publicado: (2023)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

2818. Investigating Urinalysis Criteria that Predict UTI: Impact of age, sex, and urine culture thresholds
por: Advani, Sonali, et al.
Publicado: (2023)

M2-TAMs promote immunoresistance in lung adenocarcinoma by enhancing METTL3-mediated m6A methylation
por: Wu, Lige, et al.
Publicado: (2022)

PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study
por: Cheng, Daoan, et al.
Publicado: (2023)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

Early intervention with Bifidobacterium lactis NCC2818 modulates the host-microbe interface independent of the sustained changes induced by the neonatal environment
por: Lewis, Marie C., et al.
Publicado: (2017)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Angular analysis of $ {B}^0\to {D}^{\ast -}{D}_s^{\ast +} $ with $ {D}_s^{\ast +}\to {D}_s^{+}\gamma $ decays
por: Aaij, Roel, et al.
Publicado: (2021)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Test of HQET with B^\ast, B^\ast \ast and lifetime measurements of B_s mesons and beauty baryons at DELPHI
por: Siccama, I
Publicado: (1995)

Successful Management of Osimertinib-Induced Heart Failure
por: Fukuo, Atsuko, et al.
Publicado: (2022)

High-dose-rate Brachytherapy as Adjuvant Local rEirradiation for Salvage Treatment of Recurrent breAst cancer (BALESTRA): a retrospective mono-institutional study
por: Vavassori, Andrea, et al.
Publicado: (2020)

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report
por: Wu, Lige, et al.
Publicado: (2022)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report
por: Wu, Kai, et al.
Publicado: (2022)

First Observation of the B ^\ast Dalitz Decay B ^\ast -> B\ e ^+ e ^-
por: DELPHI Collaboration
Publicado: (2018)

Antibiotic Susceptibility Testing (AST) Practices in India: Need for a National AST Forum
por: Borde, Kalyani, et al.
Publicado: (2022)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

AST Six Pack Premium
por: Basson, Craig Todd
Publicado: (1987)

$R(D^\ast)$ status
por: Wormser, Guy Henri Maurice
Publicado: (2017)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
por: Tang, Yan-Jei, et al.
Publicado: (2022)

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

B, D spectroscopy and \bar B-> D/D ^\ast /D ^\ast\astl\bar\nu
por: Bloch, D
Publicado: (1995)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Gut AstA mediates sleep deprivation-induced energy wasting in Drosophila
por: Li, Yingge, et al.
Publicado: (2023)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_thksgqdtvkrjmjke6cujtcleo4